NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
150 trialsNCT04365023 2026-02-13
TNE-bien-DIF
Assistance Publique - Hôpitaux de Paris
Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT04362436 2026-01-14
ArTisaN
Imperial College London
Phase 2 Completed
NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03217097 2025-11-21
MGMT-NET
Hospices Civils de Lyon
Phase NA Completed
NCT02678780 2025-07-24
TALENT
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03576040 2025-06-25
GAPET-NET
University Hospital, Brest
Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06983106 2025-05-21
GEP-NENs
Tongji Hospital
Completed
NCT02840149 2025-05-15
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital
Phase 3 Completed
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT06456723 2025-05-01
FETONET
Imperial College London
Phase 1/2 Completed
NCT03667092 2025-04-10
GENEBIOLuNET
University Hospital, Toulouse
Phase NA Completed
NCT04986085 2025-03-28
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT02348749 2025-03-19
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT06853457 2025-03-03
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT05246319 2025-02-12
TEGRELE
Central Hospital, Nancy, France
Completed
NCT05680675 2025-02-06
Dual-Tracer Theranostic PET
University of Utah
Phase NA Completed
NCT02691078 2025-02-04
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT04197310 2025-01-31
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05013957 2025-01-29
NEMESIs
University Hospital, Basel, Switzerland
Completed
NCT04696042 2025-01-28
AIM-NETs
Asan Medical Center
Completed
NCT06779708 2025-01-16
ECHO-NET
Istituto Clinico Humanitas
Completed
NCT02736500 2025-01-13
LuX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1/2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04510311 2025-01-10
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02724540 2025-01-06
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT05255133 2025-01-06
Liquid-NET
Universiteit Antwerpen
Phase NA Completed
NCT03278379 2024-12-24
NET-002
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03852693 2024-11-13
SurvivApp
Insel Gruppe AG, University Hospital Bern
Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06570174 2024-08-26
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Yonsei University
Phase NA Completed
NCT02923934 2024-07-24
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
Phase 2 Completed
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT03288402 2024-06-20
DIB-NET
University Hospitals Coventry and Warwickshire NHS Trust
Phase NA Completed
NCT01398306 2024-05-06
BANN
University Medical Center Groningen
Completed
NCT01849523 2024-05-06
WIN
University Medical Center Groningen
Phase NA Completed
NCT02147106 2024-05-06
VIDEO-NET
University Medical Center Groningen
Completed
NCT02472678 2024-05-06
WIN
University Medical Center Groningen
Phase NA Completed
NCT02481804 2024-05-06
DIVIT-pilot
University Medical Center Groningen
Phase NA Completed
NCT02507908 2024-05-06
5-HIAA
University Medical Center Groningen
Completed
NCT02646644 2024-05-06
HET-NET
University Medical Center Groningen
Completed
NCT02815969 2024-05-06
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
University Medical Center Groningen
Completed
NCT03143946 2024-05-06
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
University Medical Center Groningen
Phase NA Completed
NCT03870399 2024-05-06
HORMONET
AC Camargo Cancer Center
Phase 2 Completed